In a groundbreaking discovery, researchers and doctors at the Tata Institute have unveiled a revolutionary tablet that could transform the landscape of cancer treatment. Named 'R+Cu', this tablet holds the potential to prevent cancer recurrence and significantly reduce the side effects of treatments like radiation and chemotherapy by an impressive 50 percent.

The 'R+Cu' tablet contains pro-oxidant tablets infused with resveratrol and copper, a potent combination that generates oxygen radicals in the stomach. These radicals play a crucial role in destroying chromatin particles released by dying cancer cells, thereby preventing them from turning healthy cells cancerous. Moreover, this process inhibits the movement of cancer cells from one part of the body to another, a phenomenon known as 'Metastases'.

Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, emphasized the promising results of the tablet's efficacy in reducing side effects and preventing cancer recurrence during tests conducted on rats. However, while the tablet awaits approval from the Food Safety and Standards Authority of India (FSSAI), human trials are yet to be completed, a process estimated to take approximately five years.

The affordability of the 'R+Cu' tablet is a significant highlight of this breakthrough. While traditional cancer treatments often incur exorbitant costs ranging from lakhs to crores, this tablet is projected to be available for a mere ₹100, making it accessible to a wider demographic.

Dr. Badve expressed optimism about the potential impact of this tablet on cancer treatment, stating, "Tata doctors were working on this tablet for almost a decade. The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet. After getting the approval, it will be available in the market from June-July. This tablet will help to a great extent in improving cancer treatment."

Beyond its affordability, the 'R+Cu' tablet offers promise in not only preventing cancer recurrence but also in reducing the adverse effects of treatment. Researchers believe that it could be particularly effective in treating pancreatic, lung, and oral cancers, paving the way for more effective and accessible cancer care solutions.

The development of the 'R+Cu' tablet marks a significant milestone in cancer treatment, instilling hope in patients and potentially revolutionizing the oncology landscape. Its affordability, coupled with its effectiveness, positions it as a game-changer in the fight against cancer, promising brighter prospects for individuals battling this formidable disease.